small molecule

NIZATIDINE

NIZATIDINE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameNIZATIDINE
Active ingredientNIZATIDINE
Strength15MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2009
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.